606937-74-0

Basic information

• Product Name: Benzamide, 2-[(4-fluoro-2-nitrophenyl)thio]-N,N-dimethyl-
• CAS NO: 606937-74-0
• Molecular Formula: C15H13FN2O3S
• Molecular Weight: 320.344
• Mol File: 606937-74-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzamide, 2-[(4-fluoro-2-nitrophenyl)thio]-N,N-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 2-[(4-fluoro-2-nitrophenyl)thio]-N,N-dimethyl-(606937-74-0)
• EPA Substance Registry System: Benzamide, 2-[(4-fluoro-2-nitrophenyl)thio]-N,N-dimethyl-(606937-74-0)

Safety Data

• Hazardous Substances Data: 606937-74-0(Hazardous Substances Data)

Upstream product

• 506-59-2 N,N-dimethylammonium chloride 
• 345-17-5 1-chloro-4-fluoro-2-nitrobenzene 
• 147-93-3 Thiosalicylic acid 
• 627487-23-4 2-[(4-fluoro-2-nitrophenyl)thio]benzoic acid 
• 20877-02-5 2-thio-N,N-dimethylbenzamide 
• 446-09-3 2-bromo-5-fluoronitrobenzene 

Downstream Products

• 606937-83-1 N,N-dimethyl-2-(2-nitro-4-fluorophenylthio)benzylamine.BH₃ 
• 606937-75-1 1-(2-((4-fluoro-2-nitrophenyl)thio)phenyl)-N,N-dimethylmethanamine 

Relevant articles and documents

Preparation of the Serotonin Transporter PET Radiotracer 2-({2-[(Dimethylamino)methyl]phenyl}thio)-5-[18 F]fluoroaniline (4-[18 F]ADAM): Probing Synthetic and Radiosynthetic Methods

Serotonin transporters (SERTs) are involved in regulating the concentration of synaptic serotonin and present a good target for many neurologic and psychiatric disorder drugs. Positron-emission tomography (PET) is a valuable tool in both diagnosis and mon

Fluorinated phenyl thiophenyl derivatives and their use for imaging serotonin transporters

This invention relates to novel fluorinated phenyl thiphenyl (also named diarylsulfide) derivatives and their use in Positron Emission Tomagraphy (PET) imaging of Serotonin Transporters (SERTS). The present invention also provides diagnostic compositions comprising the novel compounds of the present invention, and a pharmaceutically acceptable carrier or diluent. The invention further provides a method of imaging SERTS, comprising introducing into a patient a detectable quantity of a labeled compound of the present invetion, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.